SPC368
Tafasítamab
Status:
VeittApplication date:
18.2.2022Application published:
15.3.2022Grant published:
15.2.2024
Max expiry date:
13.8.2032Medicine name:
MinjuviMedicine for children:
No
Timeline
Today
18.2.2022Application
15.3.2022Publication
15.2.2024Registration
13.8.2032Expires
Marketing license
IS authorization number:
EU/1/21/1570/001Date:
6.9.2021
Foreign authorization number:
EU/1/21/1570Date:
26.8.2021
Owner
Name:
Xencor, Inc.Address:
465 North Halstead Street, Suite 200, Pasadena, CA 91107 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2383297